Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Biotechnology

Healthcare
$10.17 -1.58%

-$0.19 today

Market cap
$857.87M
Beta
0.84
P/E (TTM)
-24.1
EPS (TTM)
-$0.49
52W Low $3.55High $26.95

Volume 0.93M

Average 1.49M

CRVS Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

No reported Net Margin figures are available to summarize.

Net Margin history

Percent of revenue · from the income statement

No Net Margin data reported for this period type.

Net Margin vs competitors

How CRVS compares with its peers on the latest reported figures

CRVS Competitors Peer median
Net Margin for CRVS and competitors
Company Period LTM level YoY 3-year change
CGENCompugen Ltd.LTM Mar 202648.0% +99.2 pp+497.8 pp
MGNXMacroGenics, Inc.LTM Mar 2026-44.8% -8.2 pp+29.9 pp
CTMXCytomX Therapeutics, Inc.LTM Mar 2026-166.4% -194.6 pp+164.0 pp
NKTRNektar TherapeuticsLTM Jun 2026-287.8% -124.7 pp+102.9 pp
CHRSCoherus Oncology, Inc.LTM Mar 2026-323.5% -257.2 pp-265.6 pp
RCUSArcus Biosciences, Inc.LTM Jun 2026-386.3% -269.5 pp+95.5 pp
IPHAInnate Pharma S.A.FY2025-1764.5% -1372.5 pp-1663.8 pp
ADAGAdagene Inc.LTM Jun 2024-3904.3% —+631.0 pp
CRVSCorvus Pharmaceuticals, Inc.FY2025— ——
CMPXCompass Therapeutics, Inc.FY2025— ——
Peer median (excluding CRVS) -305.7%-194.6 pp+99.2 pp

Competitors are the stored peer set for CRVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000105K
Gross Profit0000(105K)
Gross Margin—————
Research & Development29.12M24.47M16.53M19.39M33.72M
Selling, General & Admin9.52M8.1M6.88M8.16M9.25M
Operating Expenses38.63M32.57M23.41M27.55M42.87M
Depreciation & Amortization460K367K151K85K105K
EBITDA(42.77M)(40.94M)(26.88M)(62.21M)(15.18M)
EBITDA Margin—————
Operating Income(38.63M)(32.57M)(23.41M)(27.55M)(42.97M)
Operating Margin—————
Interest Income0654K1.58M1.82M2.51M
Interest Expense15K0000
Other Income / Expenses(4.61M)(8.74M)(3.62M)(34.75M)27.69M
Income Before Tax(43.24M)(41.31M)(27.03M)(62.29M)(15.28M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(43.24M)(41.31M)(27.03M)(62.29M)(15.28M)
Net Margin—————
EPS (Basic)(1.03)(0.89)(0.56)(1.02)(0.19)
EPS (Diluted)(1.03)(0.89)(0.56)(1.02)(0.53)
Weighted Avg Shares41.85M46.55M48.03M60.99M78.96M
Weighted Avg Shares (Diluted)41.85M46.55M48.03M60.99M79.74M

Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Intrinsic Alpha fair value

Locked

Current Price

$10.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.